Consumer News Eli Lilly Says Its New Diabetes Drug Was 94 Effective In Clinical Trials

Eli Lilly's Weight-Loss Drug Meets Primary Endpoint in Diabetes Trials

Eli Lilly said its investigational oral GLP-1 weight-loss drug, orforglipron, met its primary endpoints in two recent phase 3 trials. The medicine company said Wednesday the drug met the primary and ... Read More

Eli Lilly says its next generation weight loss drug has shown promise in early trials

Eli Lilly's next generation of weight loss drugs appear to show promise, possibly leading to even faster weight loss and added health benefits, early trial results suggest. The pharmaceutical company ... Read More

Eli Lilly Says Oral GLP-1 Drug Reduced Blood Sugar Levels In Two Late-Stage Trials

Eli Lilly and Company (LLY) on Wednesday said that its oral GLP-1 drug Orforglipron lowered blood glucose levels in two late-stage trials, confirming its potential in treating type-2 diabetes. While ... Read More

Eli Lilly oral weight loss drug succeeds in late-stage trials for diabetes

Eli Lilly (NYSE:LLY) announced on Wednesday that its oral weight loss candidate, orforglipron, reached the main goals in two Phase 3 trials for patients with type 2 diabetes, indicating its potential ... Read More

Novo, Eli Lilly oral obesity drugs included in new FDA priority voucher program

Experimental pill versions of GLP-1 weight loss drugs by Novo Nordisk and Eli Lilly will receive FDA priority review. Read more here. Read More

Eli Lilly’s weight loss and diabetes drug tops Keytruda as world’s best-selling medicine

Merck, which has claimed bragging rights as the maker of the world’s best-selling drug, Keytruda, since 2023, has officially been surpassed by Eli Lilly. Read More

Eli Lilly's orforglipron bests Farxiga, padding oral GLP-1 case with pair of phase 3 diabetes wins

Eli Lilly has guided its oral GLP-1 drug candidate orforglipron through two more late-phase tests in Type 2 diabetes, racking up wins against placebo and AstraZeneca’s Farxiga to stay on track to seek ... Read More

Eli Lilly says weight-loss pill a candidate for speedy approval under new US program

Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's new national priority voucher, suggesting it is a strong candidate for a ... Read More

Trump rolls out pricing deal with weight-loss-drug giants Eli Lilly, Novo Nordisk. Analysts say the pact raises more questions than it answers.

The Trump administration on Thursday rolled out a much-anticipated deal with drugmakers Eli Lilly and Novo Nordisk that aims to deliver lower prices for their popular GLP-1 drugs to certain Medicare ... Read More